Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

A four-month FDA delay prompted a cash-strapped biotech company to shutter. The White House’s proposed NIH cuts are drawing ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...

Headwinds in the sector are clearing. That is good news for venture firms seeking liquidity and for a stock market looking ...

What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and ...

Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...